Frontal 5-HT 2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors

1997 ◽  
Vol 133 (1) ◽  
pp. 99-101 ◽  
Author(s):  
J. M. Massou ◽  
C. Trichard ◽  
D. Attar-Levy ◽  
A. Feline ◽  
E. Corruble ◽  
...  
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Chronic Treatment ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin ◽  
Depressive Patients

Selective serotonin reuptake inhibitors: effects of chronic treatment on ethanol-reinforced behavior in mice

Alcohol ◽  
1995 ◽  
Vol 12 (3) ◽  
pp. 177-181 ◽  
Author(s):  
Joshua M. Gulley ◽  
Cecelia McNamara ◽  
Thomas J. Barbera ◽  
Mary C. Ritz ◽  
Frank R. George
Keyword(s):  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Chronic Treatment ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin

scholarly journals Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors

2001 ◽  
Vol 179 (6) ◽  
pp. 519-522 ◽  
Author(s):  
Welmoed E. E. Meijer ◽  
Marcel L. Bouvy ◽  
Eibert R. Heerdink ◽  
John Urquhart ◽  
Hubert G. M. Leufkens
Keyword(s):  
Observational Study ◽  
Serotonin Reuptake ◽  
Selective Serotonin Reuptake Inhibitors ◽  
Chronic Treatment ◽  
Prospective Observational Study ◽  
Drug Exposure ◽  
Depressive Symptomatology ◽  
Serotonin Reuptake Inhibitors ◽  
Selective Serotonin

BackgroundIn previous research, lapses in dosing of paroxetine or sertraline were associated with significantly more discontinuation symptoms and deterioration of depressive symptomatology compared with fluoxetine.AimsTo evaluate dosing lapses in patients chronically treated with selective serotonin reuptake inhibitors (SSRIs) in uncontrolled circumstances.MethodIn a prospective observational study we evaluated compliance data in chronic users of SSRIs using electronic drug exposure monitors.ResultsDuring a 3-month follow-up we found that 50/69 (72.5%) patients missed at least one dosing day and 20/69 (29.0%) missed two or more consecutive days.ConclusionsAbout 30% of patients treated with short-acting SSRIs had dosing lapses of 2 or more days, which, as described in prior studies, is long enough to result in clinically relevant deterioration of mental status.

Sign in / Sign up

Export Citation Format

Share Document